A Comparison of the Clinical Features and Comorbidities of Psoriasis and Psoriatic Arthritis: A Retrospective Study.
- Author:
Eui Hyun OH
1
;
Byeong Jin PARK
;
Hyoung Il KWON
;
Jeong Eun KIM
;
Joo Yeon KO
;
Young Suck RO
Author Information
1. Department of Dermatology, Hanyang University College of Medicine, Seoul, Korea. romio@hanyang.ac.kr
- Publication Type:Original Article
- Keywords:
Clinical features;
Psoriasis;
Psoriatic arthritis
- MeSH:
Arthritis;
Arthritis, Psoriatic*;
Blood Sedimentation;
C-Reactive Protein;
Cholesterol;
Comorbidity*;
Dermatology;
Diabetes Mellitus;
Fasting;
Glucose;
Humans;
Korea;
Prevalence;
Psoriasis*;
Retrospective Studies*;
Triglycerides
- From:Korean Journal of Dermatology
2016;54(8):608-613
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Psoriatic arthritis (PsA) is one of the inflammatory arthritis associated with psoriasis. Several studies have described the clinical difference between psoriatic patients with PsA and those without PsA. OBJECTIVE: The purpose of this study was to examine the difference in clinical features and prevalence of comorbidities between psoriatic patients with and without PsA in Korea. METHODS: We retrospectively evaluated 173 patients diagnosed with psoriasis. Patients were subdivided based on the presence or absence of PsA. We analyzed clinical manifestations including comorbidities and laboratory tests such as total cholesterol, triglyceride, C-reactive protein, erythrocyte sedimentation rate (ESR), and fasting glucose. RESULTS: Among 173 patients with psoriasis, 29 patients (16.8%) were diagnosed with PsA. The mean age of psoriasis onset for patients with PsA was 7.6 years earlier (p=0.017) than for those without PsA. The duration of psoriasis was 4.6 years longer (p<0.001) in patients with PsA than in patients without PsA. Nail involvement was more common in patients with PsA (p<0.001). There were statistically significant differences between the two groups regarding ESR levels (p=0.003) and the prevalence of diabetes mellitus (p=0.032). CONCLUSION: We found several differences in the prevalence of comorbidities, levels of inflammatory markers, and epidemiologic characteristics between psoriatic patients with and without PsA. This study may help improve strategies for the clinical approach for treating psoriasis in dermatology.
